M. Kelly

发表

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.

M. Davidson, M. Kashyap, C. Setze, 2009, Atherosclerosis.

Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis

S. Mohiuddin, K. Thakker, C. Setze, 2011, Current medical research and opinion.

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation

Tianshuang Wu, M. Kelly, A. Khotko, 2022, Dermatology and Therapy.

Combined restitutive therapy for treatment of immunosuppressive refractory Crohn disease.

K. Freeman, J. Goldsmith, M. Kelly, 2015, Journal of pediatric gastroenterology and nutrition.

A longitudinal analysis of adherence and health status in childhood diabetes.

S. Johnson, J. Silverstein, A. Tomer, 1992, Journal of pediatric psychology.

Comparison of the Gastrointestinal Absorption and Bioavailability of Fenofibrate and Fenofibric Acid in Humans

J. Ansquer, Tong Zhu, Jean-Claude Ansquer, 2010, Journal of clinical pharmacology.

Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.

A. Goldberg, H. Knapp, C. Setze, 2010, American heart journal.

Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.

R. Rosenson, M. Davidson, K. Thakker, 2012, Journal of clinical lipidology.

One-Year Efficacy and Safety of Rosuvastatin + Fenofibric Acid Combination Therapy in Patients with Mixed Dyslipidemia

K. Ferdinand, M. Davidson, C. Setze, 2012, American Journal of Cardiovascular Drugs.

Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies

C. Pepine, L. Williams, A. Gold, 2010, Clinical cardiology.

Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia

J. Mckenney, L. Williams, A. Gold, 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.

A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.

L. Williams, C. Setze, D. Weinstein, 2013, Clinical therapeutics.

Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy: Randomized, Placebo-Controlled Study (FIRST)

C. Ballantyne, R. Rosenson, T. Mazzone, 2014, Arteriosclerosis, thrombosis, and vascular biology.

Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides

C. Ballantyne, K. Thakker, C. Setze, 2011, Cardiovascular Drugs and Therapy.

Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins

H. Bays, M. Davidson, C. Setze, 2008, Clinical drug investigation.

Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.

A. Goldberg, C. Pepine, V. Bittner, 2011, The American journal of cardiology.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.

C. Pepine, S. Mohiuddin, C. Setze, 2009, American heart journal.

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus

R. Rosenson, L. Williams, B. Hirshberg, 2010, Cardiovascular Drugs and Therapy.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.

C. Ballantyne, A. Goldberg, H. Bays, 2009, The American journal of cardiology.

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia.

H. Bays, S. Mohiuddin, C. Setze, 2008, Journal of clinical lipidology.

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia

J. Mckenney, H. Bays, K. Thakker, 2010, Diabetes Care.

Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination

M. Kipnes, C. Setze, E. Roth, 2010, Clinical Drug Investigation.

Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.

A. Goldberg, C. Pepine, M. Davidson, 2009, Journal of clinical lipidology.

Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus

K. Cusi, M. Davidson, K. Thakker, 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

T. Edeki, M. Rieser, L. Gustavson, 2006, Clinical therapeutics.

ABT‐335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans

B. Hosmane, W. Awni, T. Zhu, 2009, Journal of clinical pharmacology.

Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy: Randomized, Placebo-Controlled Study (FIRST)

C. Ballantyne, R. Rosenson, T. Mazzone, 2014, Arteriosclerosis, thrombosis, and vascular biology.